ArticleTheranostics2026

Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell maintenance and immune evasion in enzalutamide-resistant prostate cancer.

Feifei Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.